Journal of Diabetes & Metabolic Disorders (2020) 19:1979–1993 https://doi.org/10.1007/s40200-020-00647-5 REVIEW ARTICLE Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases Vidul Goenka1 & Tanhai Borkar1 & Aska Desai1 & Raunak Kumar Das2 Received: 8 April 2020 /Accepted: 24 September 2020 © Springer Nature Switzerland AG 2020

Diabetes Volume 64, February 2015 Per-Ola Carlsson,1,2 Erik Schwarcz,3 Olle Korsgren,4 and Katarina Le Blanc5 Preserved b-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells Diabetes 2015;64:587–592 | DOI: 10.2337/db14-0656

Endocrine Journal 2013, 60 (3), 347-357 Original Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus Jianxia Hu1)*, Xiaolong Yu2) *, Zhongchao Wang2), Fang Wang2), Li Wang1), Hong Gao1), Ying Chen2), Wenjuan Zhao2), Zhaotong Jia2), Shengli Yan2) and Yangang Wang1) 1) Stem Cell Research Center, the Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China 2) Endocrinology Department, the Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China

Stem Cells and Development © Mary Ann Liebert, Inc. DOI: 10.1089/scd.2016.0275 Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cells and Mononuclear Cells Transplantation in Type 2 Diabetes Mellitus: A Randomized Placebo-Controlled Comparative Study Short Running Title- Stem cells transplantation in T2DM Shobhit Bhansali, Pinaki Dutta, Vinod Kumar, Mukesh Kumar Yadav, Ashish Jain, Sunder Mudaliar, Shipra Bhansali, Ratti Ram Sharma, Vivekanand Jha, Neelam Marwaha, Niranjan Khandelwal, Anand Srinivasan, Naresh Sachdeva, Meredith Hawkins, and Anil Bhansali,

Hindawi International Journal of Endocrinology Volume 2021, Article ID 9938658, 11 pages https://doi.org/10.1155/2021/9938658 Review Article Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus Qiulan Huang , Yanting Huang , and Jianping Liu Department of Endocrinology, e Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China Correspondence should be addressed to Jianping Liu; liujpnfm@163.com Received 10 March 2021; Accepted 19 May 2021; Published 28 May 2021 Academic Editor: Andrea Tura Copyright © 2021 Qiulan Huang et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Mesenchymal stem cells (MSCs) are adult stem cells (ASCs) known for repairing damaged cells, exerting anti-inflammatory responses and producing immunoregulatory effects that can be significantly induced into insulin-producing cells (IPCs), providing an inexhaustible supply of functional β cells for cell replacement therapy and disease modeling for diabetes. MSC therapy may be the most promising strategy for diabetes mellitus because of these significant merits. In this paper, we focused on MSC therapy for diabetes.

Ứng dụng tế bào gốc trung mô trong điều trị bệnh đái tháo đường Therapeutic potential of mesenchymal stem cells in treating both types of diabetes mellitus and associated diseases - PMC (nih.gov) (2020) Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus (hindawi.com) (2021)